Comparative Pharmacology
Head-to-head clinical analysis: MPI STANNOUS DIPHOSPHONATE versus QUADRAMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI STANNOUS DIPHOSPHONATE versus QUADRAMET.
MPI STANNOUS DIPHOSPHONATE vs QUADRAMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stannous diphosphonate is a radiopharmaceutical agent that forms a complex with technetium-99m; it localizes to areas of increased bone turnover by chemisorption to hydroxyapatite crystals, thereby enabling bone scintigraphy.
Samarium Sm 153 lexidronam is a radiolabeled agent that localizes to areas of osteoblastic bone activity. The samarium-153 isotope emits beta particles and gamma photons, delivering radiation to the bone and surrounding tissues. This results in the destruction of malignant cells in bone metastases.
Adult: 1-4 mg administered intravenously, single dose for bone scintigraphy.
1.0 mCi/kg (37 MBq/kg) intravenously as a single dose.
None Documented
None Documented
Terminal elimination half-life: Approximately 2.5 hours for the diphosphonate component; the stannous ion is cleared more slowly. Clinically, this allows rapid bone uptake and background clearance for imaging within 2–4 hours post-injection.
Terminal half-life: 6–8 hours (prolonged in renal impairment; may exceed 20 hours in CrCl <30 mL/min).
Renal: >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal: Minimal (<2%).
Renal: 65% as unchanged drug; biliary/fecal: 20% as metabolites; remainder as other minor metabolites.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical